Luspatercept Gets Priority Review for First-Line Tx of Anemia in Lower-Risk MDS
BMS is seeking approval of Reblozyl (lupatercept) as a first-line treatment of anemia in adults with lower-risk MDS.
Stay updated with breaking news from Noah Berkowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BMS is seeking approval of Reblozyl (lupatercept) as a first-line treatment of anemia in adults with lower-risk MDS.
The treatment showed significant improvement in patients in patients who require frequent blood transfusions and are at risk of infection.
Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an... | May 1, 2023
Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...
The FDA has granted a priority review to the supplemental biologics license application seeking to expand the current indication of luspatercep to include treatment of anemia in patients with very low- to intermediate-risk myelodysplastic syndrome who have not previously received erythropoiesis-stimulating agents and who may require red blood cell transfusions.